Partners

To facilitate the marketing, distribution and development of its products, AMAG Pharmaceuticals has entered into several strategic relationships with established pharmaceutical companies.

AMAG Pharmaceuticals' principal marketing and development partners worldwide are listed below:

3SBio, Inc.
Strategic partnership to develop and commercialize ferumoxytol as an intravenous iron replacement therapeutic agent to treat iron deficiency anemia in chronic kidney disease in China.

Bayer Healthcare Pharmaceuticals
Feridex I.V.® is marketed in the United States by Bayer Healthcare Pharmaceuticals. If you have questions or would like product information about Feridex I.V., please contact Bayer Healthcare Pharmaceuticals at 1-877-BAYER50.

Guerbet
Feridex I.V.® (tradename Endorem™) is marketed in various countries in the European Union, South America, the Middle East, Southeast Asia, South Africa and eastern Europe. GastroMARK® (tradename Lumirem™) is marketed in various countries in the European Union, South America, the Middle East, Southeast Asia, Africa and eastern Europe. Combidex® (tradename Sinerem™) is marketed in various countries in the European Union, South America, the Middle East, Southeast Asia, Africa, Mexico and eastern Europe.

Covidien, Ltd.
GastroMARK® is marketed in the United States by Covidien, Ltd. For more information regarding GastroMARK®, please contact Covidien, Ltd. at 1 (888) 744-1414.

TaeJoon Pharmaceuticals
Feridex® is marketed by TaeJoon Pharmaceuticals in South Korea.